CODX
Co-Diagnostics, Inc.
Price Chart
Latest Quote
$3.33
-0.51 (-13.28%)
Current Price
| Previous Close | $3.84 |
| Open | $3.73 |
| Day High | $3.82 |
| Day Low | $2.95 |
| Volume | 470,302 |
Stock Information
| Shares Outstanding | 3.69M |
| Total Debt | $2.03M |
| Cash Equivalents | $8.23M |
| Revenue | $718K |
| Net Income | $-48.50M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $12.42M |
| EPS (TTM) | $-32.26 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $7.63M |
| Sales | $718K |
| Income | $-48.50M |
| Book/sh | $4.45 |
| Cash/sh | $2.23 |
| Employees | 115 |
Financial Ratios
| Quick Ratio | 1.94 |
| Current Ratio | 2.28 |
| Debt/Eq | 12.66 |
Returns & Margins
| ROA | -52.09% |
| ROE | -151.66% |
| Gross Margin | 45.06% |
| Operating Margin | -6309.12% |
Ownership
| Insider Ownership | 3.60% |
| Institutional Ownership | 9.53% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.28 |
| P/S | 17.29 |
| P/B | 0.76 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $5.58 |
| SMA50 | $3.22 |
| SMA200 | $6.34 |
| RSI | 14.85 |
| ATR | 1.2170 |
| Shares Float | 3.50M |
| Short Float | 9.80% |
| Short Ratio | 0.02 |
| Rel Volume | 0.06 |
Performance History
| Week | -28.30% |
| Month | +71.07% |
| Quarter | +27.17% |
| 6 Months | -54.34% |
| YTD | -39.39% |
| Year | -58.55% |
| 3 Years | -89.40% |
| 5 Years | -98.73% |
| 10 Years | -98.07% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $3.37 | 624,100 |
| 2026-06-17 | $3.33 | 472,400 |
| 2026-06-16 | $3.84 | 349,700 |
| 2026-06-15 | $3.78 | 356,400 |
| 2026-06-12 | $4.29 | 435,100 |
| 2026-06-11 | $4.70 | 178,000 |
| 2026-06-10 | $4.88 | 572,100 |
| 2026-06-09 | $4.50 | 324,900 |
| 2026-06-08 | $5.05 | 467,100 |
| 2026-06-05 | $5.63 | 669,700 |
| 2026-06-04 | $5.76 | 1,930,700 |
| 2026-06-03 | $5.17 | 1,180,600 |
| 2026-06-02 | $6.22 | 4,721,800 |
| 2026-06-01 | $6.20 | 2,603,600 |
| 2026-05-29 | $8.53 | 3,382,200 |
| 2026-05-28 | $11.19 | 19,381,800 |
| 2026-05-27 | $7.30 | 6,859,600 |
| 2026-05-26 | $9.11 | 50,928,700 |
| 2026-05-22 | $5.07 | 10,017,900 |
| 2026-05-21 | $3.71 | 91,560,700 |
| 2026-05-20 | $2.39 | 14,205,300 |
| 2026-05-19 | $1.97 | 119,828,000 |
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
đ° Latest News
Is Co-Diagnostics National Securityâs Next Diagnostic Pick?
MarketBeat âĸ 2026-05-28T15:00:00Z
Co-Diagnostics (CODX) Q4 2025 Earnings Transcript
Motley Fool âĸ 2026-05-27T20:52:47Z
Top Midday Gainers
MT Newswires âĸ 2026-05-26T17:54:49ZCODX Stock Explodes Over 630% In Six Sessions â Retail Traders Bet The Rally Isnât Over Yet
Stocktwits âĸ 2026-05-26T17:00:58Z
Co-Diagnostics Develops Ebola Assay Strategy Following WHO Emergency Alert (CODX)
InvestorsHub âĸ 2026-05-19T14:34:19Z
Co-Diagnostics (CODX) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-15T17:31:12Z
Co-Diagnostics, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-15T12:30:00Z
Co-Diagnostics Inc (CODX) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial ...
GuruFocus.com âĸ 2026-05-15T05:02:28ZCoMira concludes lease agreement for plant in Sudair Industrial City, Saudi Arabia
Medical Device Network âĸ 2026-05-11T09:43:39Z
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates
Zacks âĸ 2026-05-06T22:30:16Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $222,377 | $999,124 | $4,184,949 | $5,481,093 |
| Cost Of Revenue | $222,377 | $999,124 | $4,184,949 | $5,481,093 |
| Total Revenue | $622,489 | $3,915,160 | $6,812,038 | $34,218,209 |
| Operating Revenue | $622,489 | $3,915,160 | $6,812,038 | $34,218,209 |
| Expenses | ||||
| Total Expenses | $31,905,841 | $43,996,470 | $49,518,272 | $45,809,500 |
| Other Income Expense | $-17,521,494 | $1,407,845 | $3,433,765 | $-7,959,988 |
| Net Non Operating Interest Income Expense | $292,932 | $1,091,825 | $1,161,913 | $704,045 |
| Operating Expense | $31,683,464 | $42,997,346 | $45,333,323 | $40,328,407 |
| Selling And Marketing Expense | $2,381,131 | $4,483,339 | $6,860,815 | $7,344,628 |
| General And Administrative Expense | $9,058,283 | $16,157,152 | $14,279,441 | $14,262,963 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-46,895,936 | $-37,639,008 | $-35,332,865 | $-14,238,249 |
| Net Interest Income | $292,932 | $1,091,825 | $1,161,913 | $704,045 |
| Interest Income | $292,932 | $1,091,825 | $1,161,913 | $704,045 |
| Normalized Income | $-29,997,424 | $-38,898,198 | $-38,422,613 | $-8,479,850 |
| Net Income From Continuing And Discontinued Operation | $-46,895,936 | $-37,639,008 | $-35,332,865 | $-14,238,249 |
| Total Operating Income As Reported | $-50,165,352 | $-40,081,310 | $-42,706,234 | $-26,979,837 |
| Net Income Common Stockholders | $-46,895,936 | $-37,639,008 | $-35,332,865 | $-14,238,249 |
| Net Income | $-46,895,936 | $-37,639,008 | $-35,332,865 | $-14,238,249 |
| Net Income Including Noncontrolling Interests | $-46,895,936 | $-37,639,008 | $-35,332,865 | $-14,238,249 |
| Net Income Continuous Operations | $-46,895,936 | $-37,639,008 | $-35,332,865 | $-14,238,249 |
| Pretax Income | $-48,511,914 | $-37,581,640 | $-38,110,556 | $-18,847,234 |
| Special Income Charges | $-18,158,558 | $723,167 | $1,090,003 | $-7,627,019 |
| Earnings From Equity Interest | $-46,301 | $-186,067 | $100,703 | $-332,969 |
| Interest Income Non Operating | $292,932 | $1,091,825 | $1,161,913 | $704,045 |
| Operating Income | $-31,283,352 | $-40,081,310 | $-42,706,234 | $-11,591,291 |
| Depreciation Amortization Depletion Income Statement | $1,106,808 | $1,377,266 | $1,230,474 | $1,282,718 |
| Depreciation And Amortization In Income Statement | $1,106,808 | $1,377,266 | $1,230,474 | $1,282,718 |
| Gross Profit | $400,112 | $2,916,036 | $2,627,089 | $28,737,116 |
| Per Share | ||||
| Diluted EPS | $-35.25 | $-37.22 | $-36.00 | $-13.50 |
| Basic EPS | $-35.25 | $-37.22 | $-36.00 | $-13.50 |
| Other | ||||
| Tax Effect Of Unusual Items | $-576,681 | $334,722 | $243,314 | $-1,868,620 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-12,701,351 | $-40,297,956 | $-44,808,822 | $-2,681,554 |
| Total Unusual Items | $-17,475,193 | $1,593,912 | $3,333,062 | $-7,627,019 |
| Total Unusual Items Excluding Goodwill | $-17,475,193 | $1,593,912 | $3,333,062 | $-7,627,019 |
| Reconciled Depreciation | $1,106,808 | $1,377,266 | $1,230,474 | $1,282,718 |
| EBITDA (Bullshit earnings) | $-30,176,544 | $-38,704,044 | $-41,475,760 | $-10,308,573 |
| EBIT | $-31,283,352 | $-40,081,310 | $-42,706,234 | $-11,591,291 |
| Diluted Average Shares | $1,330,199 | $1,011,178 | $978,219 | $1,049,300 |
| Basic Average Shares | $1,330,199 | $1,011,178 | $978,219 | $1,049,300 |
| Diluted NI Availto Com Stockholders | $-46,895,936 | $-37,639,008 | $-35,332,865 | $-14,238,249 |
| Tax Provision | $-1,615,978 | $57,368 | $-2,777,691 | $-4,608,985 |
| Gain On Sale Of Ppe | $-82,421 | $8,291 | $-2,578 | $-138,117 |
| Impairment Of Capital Assets | $18,882,000 | $0 | $0 | $15,388,546 |
| Restructuring And Mergern Acquisition | $-805,863 | $-714,876 | $-1,092,581 | $-7,899,644 |
| Gain On Sale Of Security | $683,365 | $870,745 | $2,243,059 | - |
| Research And Development | $19,137,242 | $20,979,589 | $22,962,593 | $17,438,098 |
| Selling General And Administration | $11,439,414 | $20,640,491 | $21,140,256 | $21,607,591 |
| Other Gand A | $9,058,283 | $16,157,152 | $14,279,441 | $14,262,963 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $13,409,664 | $27,774,157 | $59,609,948 | $87,751,661 |
| Total Assets | $24,742,585 | $63,563,158 | $95,320,660 | $123,086,281 |
| Total Non Current Assets | $11,049,120 | $31,271,460 | $33,179,552 | $30,352,610 |
| Goodwill And Other Intangible Assets | $7,219,000 | $26,101,000 | $26,403,667 | $26,768,333 |
| Other Intangible Assets | $7,219,000 | $26,101,000 | $26,403,667 | $26,768,333 |
| Current Assets | $13,693,465 | $32,291,698 | $62,141,108 | $92,733,671 |
| Other Current Assets | $581,527 | $1,338,762 | $1,597,114 | $761,187 |
| Inventory | $992,397 | $1,072,724 | $1,664,725 | $5,310,473 |
| Receivables | $234,934 | $132,570 | $330,881 | $5,399,142 |
| Taxes Receivable | $44,559 | $0 | $26,955 | $1,870,419 |
| Accounts Receivable | $190,375 | $132,570 | $303,926 | $3,453,723 |
| Allowance For Doubtful Accounts Receivable | $-40,377 | $-110,055 | $-200,338 | $-3,098,526 |
| Gross Accounts Receivable | $230,752 | $242,625 | $504,264 | $6,552,249 |
| Cash Cash Equivalents And Short Term Investments | $11,884,607 | $29,747,642 | $58,548,388 | $81,262,869 |
| Cash And Cash Equivalents | $11,884,607 | $2,936,544 | $14,916,878 | $22,973,803 |
| Cash Financial | $11,884,607 | $2,936,544 | $4,317,449 | $12,834,444 |
| Cash Equivalents | - | $0 | $10,599,429 | $10,139,359 |
| Notes Receivable | - | - | $0 | $75,000 |
| Non Current Note Receivables | - | - | - | $0 |
| Non Current Deferred Assets | - | - | - | - |
| Non Current Deferred Taxes Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $1,236,559 | $2,152,179 | $2,990,567 | $347,917 |
| Long Term Debt And Capital Lease Obligation | $574,301 | $1,236,560 | $2,152,180 | $50,708 |
| Current Debt And Capital Lease Obligation | $662,258 | $915,619 | $838,387 | $297,209 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,113,921 | $9,688,001 | $9,307,045 | $8,566,287 |
| Total Non Current Liabilities Net Minority Interest | $574,301 | $2,372,283 | $3,559,475 | $4,692,864 |
| Tradeand Other Payables Non Current | $0 | $713,643 | $659,186 | $1,181,284 |
| Current Liabilities | $3,539,620 | $7,315,718 | $5,747,570 | $3,873,423 |
| Other Current Liabilities | $119,036 | $502,819 | $891,666 | $1,689,471 |
| Current Deferred Liabilities | $14,800 | $40,857 | $362,449 | $0 |
| Payables And Accrued Expenses | $2,743,526 | $5,856,423 | $3,655,068 | $1,886,743 |
| Payables | $1,878,225 | $3,294,254 | $1,482,109 | $952,296 |
| Accounts Payable | $1,878,225 | $3,294,254 | $1,482,109 | $952,296 |
| Other Non Current Liabilities | - | $422,080 | $748,109 | $1,042,885 |
| Non Current Deferred Liabilities | - | - | $0 | $2,417,987 |
| Non Current Deferred Taxes Liabilities | - | - | $0 | $2,417,987 |
| Total Tax Payable | - | - | - | $0 |
| Income Tax Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $20,628,664 | $53,875,157 | $86,013,615 | $114,519,994 |
| Total Equity Gross Minority Interest | $20,628,664 | $53,875,157 | $86,013,615 | $114,519,994 |
| Stockholders Equity | $20,628,664 | $53,875,157 | $86,013,615 | $114,519,994 |
| Gains Losses Not Affecting Retained Earnings | $0 | $418,443 | $146,700 | $293,140 |
| Retained Earnings | $-80,373,539 | $-33,477,603 | $4,598,166 | $39,931,031 |
| Long Term Equity Investment | $350,569 | $294,304 | $773,382 | $672,679 |
| Other Equity Adjustments | - | $418,443 | $146,700 | $293,140 |
| Other | ||||
| Treasury Shares Number | $161,622 | $161,622 | $161,622 | $129,388 |
| Ordinary Shares Number | $2,095,030 | $1,101,784 | $1,041,988 | $1,029,086 |
| Share Issued | $2,256,652 | $1,263,406 | $1,203,610 | $1,158,474 |
| Tangible Book Value | $13,409,664 | $27,774,157 | $59,609,948 | $87,751,661 |
| Invested Capital | $20,628,664 | $53,875,157 | $86,013,615 | $114,519,994 |
| Working Capital | $10,153,845 | $24,975,980 | $56,393,538 | $88,860,248 |
| Capital Lease Obligations | $1,236,559 | $2,152,179 | $2,990,567 | $347,917 |
| Total Capitalization | $20,628,664 | $53,875,157 | $86,013,615 | $114,519,994 |
| Treasury Stock | $15,575,795 | $15,575,795 | $15,575,795 | $14,211,866 |
| Additional Paid In Capital | $116,510,298 | $102,472,210 | $96,808,436 | $88,472,935 |
| Capital Stock | $67,700 | $37,902 | $36,108 | $34,754 |
| Common Stock | $67,700 | $37,902 | $36,108 | $34,754 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $574,301 | $1,236,560 | $2,152,180 | $50,708 |
| Current Deferred Revenue | $14,800 | $40,857 | $362,449 | $0 |
| Current Capital Lease Obligation | $662,258 | $915,619 | $838,387 | $297,209 |
| Current Accrued Expenses | $865,301 | $2,562,169 | $2,172,959 | $934,447 |
| Investments And Advances | $350,569 | $294,304 | $773,382 | $672,679 |
| Investmentsin Joint Venturesat Cost | $350,569 | $294,304 | $773,382 | $672,679 |
| Net PPE | $3,479,551 | $4,876,156 | $6,002,503 | $2,911,598 |
| Accumulated Depreciation | $-3,909,291 | $-3,280,843 | $-2,232,495 | $-1,372,248 |
| Gross PPE | $7,388,842 | $8,156,999 | $8,234,998 | $4,283,846 |
| Leases | $968,573 | $947,674 | $548,648 | $224,957 |
| Other Properties | $6,246,601 | $7,035,657 | $7,512,682 | $3,946,845 |
| Machinery Furniture Equipment | $173,668 | $173,668 | $173,668 | $112,044 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $512,186 | $567,281 | $700,467 | $1,327,264 |
| Raw Materials | $480,211 | $505,443 | $964,258 | $3,983,209 |
| Other Short Term Investments | $0 | $26,811,098 | $43,631,510 | $58,289,066 |
| Goodwill | - | - | - | $0 |
| Non Current Accrued Expenses | - | - | - | - |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-29,836,974 | $-29,903,397 | $-23,447,171 | $5,141,225 |
| Operating Activities | ||||
| Operating Cash Flow | $-29,136,927 | $-29,155,045 | $-22,081,865 | $6,568,737 |
| Cash Flow From Continuing Operating Activities | $-29,136,927 | $-29,155,045 | $-22,081,865 | $6,568,737 |
| Operating Gains Losses | $-554,643 | $-692,969 | $-2,341,184 | $471,086 |
| Investing Activities | ||||
| Capital Expenditure | $-700,047 | $-748,352 | $-1,365,306 | $-1,427,512 |
| Investing Cash Flow | $26,273,407 | $17,070,797 | $15,388,869 | $-58,168,172 |
| Cash Flow From Continuing Investing Activities | $26,273,407 | $17,070,797 | $15,388,869 | $-58,168,172 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $11,799,083 | $103,914 | $0 | - |
| Financing Cash Flow | $11,811,583 | $103,914 | $-1,363,929 | $-14,033,996 |
| Cash Flow From Continuing Financing Activities | $11,811,583 | $103,914 | $-1,363,929 | $-14,033,996 |
| Net Common Stock Issuance | $11,799,083 | $103,914 | $-1,363,929 | $-14,211,866 |
| Common Stock Issuance | $11,799,083 | $103,914 | $0 | - |
| Repurchase Of Capital Stock | - | $0 | $-1,363,929 | $-14,211,866 |
| Other | ||||
| Income Tax Paid Supplemental Data | $858,870 | $0 | $55,975 | $4,498,742 |
| End Cash Position | $11,884,607 | $2,936,544 | $14,916,878 | $22,973,803 |
| Beginning Cash Position | $2,936,544 | $14,916,878 | $22,973,803 | $88,607,234 |
| Changes In Cash | $8,948,063 | $-11,980,334 | $-8,056,925 | $-65,633,431 |
| Proceeds From Stock Option Exercised | $12,500 | $0 | $0 | $177,870 |
| Net Investment Purchase And Sale | $27,076,020 | $17,962,899 | $16,754,175 | $-56,740,660 |
| Sale Of Investment | $33,666,959 | $58,765,487 | $127,251,619 | $11,255,266 |
| Purchase Of Investment | $-6,590,939 | $-40,802,588 | $-110,497,444 | $-67,995,926 |
| Net Business Purchase And Sale | $-102,566 | $-143,750 | $0 | $0 |
| Purchase Of Business | $-102,566 | $-143,750 | $0 | - |
| Net PPE Purchase And Sale | $-700,047 | $-748,352 | $-1,365,306 | $-1,427,512 |
| Purchase Of PPE | $-700,047 | $-748,352 | $-1,365,306 | $-1,427,512 |
| Change In Working Capital | $-3,167,199 | $2,754,651 | $5,641,341 | $6,191,953 |
| Change In Other Working Capital | $-26,057 | $-321,592 | $362,449 | $-150,000 |
| Change In Payables And Accrued Expense | $-3,826,540 | $2,212,307 | $1,246,228 | $-4,685,071 |
| Change In Payable | $-3,826,540 | $2,212,307 | $1,246,228 | $-4,685,071 |
| Change In Account Payable | $-3,112,897 | $2,157,850 | $1,768,326 | $-2,483,821 |
| Change In Tax Payable | $-713,643 | $54,457 | $-522,098 | $-2,201,250 |
| Change In Income Tax Payable | $-713,643 | $54,457 | $-522,098 | $-2,201,250 |
| Change In Prepaid Assets | $585,926 | $412,056 | $1,082,536 | $-224,094 |
| Change In Inventory | $131,271 | $265,489 | $413,140 | $-3,673,309 |
| Change In Receivables | $-31,799 | $186,391 | $2,536,988 | $14,924,427 |
| Changes In Account Receivables | $-31,799 | $186,391 | $2,536,988 | $14,924,427 |
| Other Non Cash Items | $-679,060 | $-701,366 | $-3,462,576 | $-12,679,671 |
| Stock Based Compensation | $2,248,053 | $5,434,904 | $8,336,855 | $7,543,223 |
| Provisionand Write Offof Assets | $-26,006 | $-15,035 | $612,809 | $2,461,032 |
| Asset Impairment Charge | $18,831,056 | $326,512 | $3,233,281 | $15,536,645 |
| Depreciation Amortization Depletion | $1,106,808 | $1,377,266 | $1,230,474 | $1,282,718 |
| Depreciation And Amortization | $1,106,808 | $1,377,266 | $1,230,474 | $1,282,718 |
| Earnings Losses From Equity Investments | $46,301 | $186,067 | $-100,703 | $332,969 |
| Gain Loss On Investment Securities | $-683,365 | $-870,745 | $-2,243,059 | - |
| Net Income From Continuing Operations | $-46,895,936 | $-37,639,008 | $-35,332,865 | $-14,238,249 |
| Common Stock Payments | - | $0 | $-1,363,929 | $-14,211,866 |
| Deferred Tax | - | $0 | $-2,417,987 | $-4,810,457 |
| Deferred Income Tax | - | $0 | $-2,417,987 | $-4,810,457 |
| Interest Paid Supplemental Data | - | - | $0 | $0 |
| Sale Of Business | - | - | - | $0 |
Fetched: 2026-06-16